14 reports

  • 8.5 ABBVIE

The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, f

  • Cystic Fibrosis
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.

Engages in the development of drugs for hematologic, autoimmune, and neurological disorders.

  • Cystic Fibrosis
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

It is one of the most common types of genetic diseases observed in Caucasian children.

  • Cystic Fibrosis
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.

She was subsequently appointed President and Chief Executive Officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer.

  • Cystic Fibrosis
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Pharmaxis Ltd

The autoimmune disease affects about ##% of the population and is caused by alimentary gluten in genetically susceptible individuals.

  • Cystic Fibrosis
  • Europe
  • World
  • Product Initiative
  • Zedira GmbH
  • CYSTIC FIBROSIS - PIPELINE BY IMMUN SYSTEM IMS AB, H2 2018
  • CYSTIC FIBROSIS - PIPELINE BY INSMED INC, H2 2018

The company develops gene therapies for cardiovascular, respiratory, autoimmune, ophthalmologic diseases, cancer, and others.

  • Cystic Fibrosis
  • United States
  • Company
  • Product Initiative
  • Galapagos NV

The autoimmune disease affects about ##% of the population and is caused by alimentary gluten in genetically susceptible individuals.

  • Cystic Fibrosis
  • Drug Discovery And Development
  • Europe
  • World
  • Product Initiative

Its pharmaceutical division develops and manufactures products to treat and diagnose diseases in the following areas: anaemia, inflammatory and autoimmune diseases, central nervous system, cardiovascular diseases, infectious diseases, metabolic disorders, cancer,

  • Cardiology
  • Cystic Fibrosis
  • Healthcare
  • Therapy
  • PTC Therapeutics, Inc.

Its pharmaceutical division develops and manufactures products to treat and diagnose diseases in the following areas: anaemia, inflammatory and autoimmune diseases, central nervous system, cardiovascular diseases, infectious diseases, metabolic disorders, cancer,

  • Cardiology
  • Cystic Fibrosis
  • Healthcare
  • Therapy
  • PTC Therapeutics, Inc.
  • CYSTIC FIBROSIS - PIPELINE BY INVION LTD, H1 2018
  • CYSTIC FIBROSIS - PIPELINE BY INSMED INC, H1 2018

The company develops gene therapies for cardiovascular, respiratory, autoimmune, ophthalmologic diseases, and cancer.

  • Cystic Fibrosis
  • United States
  • Company
  • Product Initiative
  • Galapagos NV

May ##, 2012 Galapagos NV initiated its second Phase IIa clinical study with GLPG##, a new Janus kinase ## (JAK##) inhibitor being developed to treat multiple autoimmune diseases, such as rheumatoid arthritis (RA).

  • Cystic Fibrosis
  • Therapy
  • World
  • Product Initiative
  • Galapagos NV

It focuses on therapy areas such as respiratory, inflammation, autoimmune disease (RIA); cardiovascular and metabolic disease (CVMD); and cancer, besides infection and neurological diseases.

  • Antibiotic Resistance
  • Cystic Fibrosis
  • United States
  • Product Initiative
  • Insmed Incorporated

Lundbeck A/ S Private DEAL REPORT: BIOFOCUS SIGNS AGREEMENT WITH ONO PHARMACEUTICAL Ono Pharmaceutical Co., Ltd., a Japan-based specialty pharmaceutical company, has signed a collaboration agreement with BioFocus DPI plc to discover targets in the field of autoimmune disease.

  • Cystic Fibrosis
  • Healthcare
  • Hospital
  • Pharmaceutical
  • BioFocus DPI Limited

One example of such a multifactorial disease is Alzheimer' s disease.

  • Cystic Fibrosis
  • Genetic Disorder
  • Laboratory
  • United States
  • Sequenom, Inc.